| Literature DB >> 29807441 |
Sai Krupa Das1, Shawn T Mason2, Taylor A Vail1, Gail V Rogers1, Kara A Livingston1, Jillian G Whelan1, Meghan K Chin1, Caroline M Blanchard1, Jennifer L Turgiss2, Susan B Roberts1.
Abstract
PURPOSE: Programs focused on employee well-being have gained momentum in recent years, but few have been rigorously evaluated. This study evaluates the effectiveness of an intervention designed to enhance vitality and purpose in life by assessing changes in employee quality of life (QoL) and health-related behaviors.Entities:
Keywords: behavior change intervention; employee wellness program; purpose in life; quality of life; well-being intervention
Mesh:
Year: 2018 PMID: 29807441 PMCID: PMC7323760 DOI: 10.1177/0890117118776875
Source DB: PubMed Journal: Am J Health Promot ISSN: 0890-1171
Figure 1.CONSORT chart: Participant enrollment and retention.
Figure 2.Johnson & Johnson Human Performance Institute 2.5-Day Course Outline.
Participant Characteristics at Baseline.
| Control Group (CG), n = 77 | Intervention Group (IG), n = 163 | ||
|---|---|---|---|
| Female sex, % | 47 (61.0%) | 93 (57.0%) | .559 |
| Age, mean (SD), years | 45.9 (10.3) | 46.7 (11.1) | .564 |
| Hispanic ethnicity, % | 7 (9.1) | 11 (6.7) | .525d |
| Race, % | |||
| White | 62 (80.5) | 124 (76.1) | .671 |
| Black/African American | 4 (5.2) | 8 (4.9) | |
| Asian | 5 (6.5) | 19 (11.6) | |
| Otherb | 6 (7.8) | 12 (7.4) | |
| Marital status, % | |||
| Married or living with partner | 53 (68.8) | 114 (69.9) | .862 |
| Otherc | 24 (31.2) | 49 (30.1) | |
| Annual household income, % | |||
| US$0-US$59 999 | 10 (13.0) | 11 (6.7) | .144d |
| US$60 000-US$99 999 | 15 (19.5) | 42 (25.8) | |
| US$100 000+ | 49 (63.6) | 108 (66.3) | |
| Unknown | 3 (3.9) | 2 (1.2) | |
| Highest level of education completed, % | |||
| 12th grade/GED, some college/associate’s | 10 (13.0) | 26 (16.0) | .808d |
| Bachelor’s (includes multiple degrees) | 28 (36.4) | 63 (38.7) | |
| Graduate degree (doctoral or nondoctoral) | 37 (48.0) | 74 (45.4) | |
| Unknown | 2 (2.6) | 0 (0.0) | |
| Current smoker, %e | 1 (1.3) | 8 (4.9) | .280 |
| Ever smoked, %f | 16 (20.8) | 34 (20.9) | .998 |
| Chronic illness, %g | |||
| High blood pressure | 0 (0.0) | 9 (5.5) | .061 |
| High cholesterol | 0 (0.0) | 2 (1.2) | .999 |
| Diabetes | 1 (1.3) | 2 (1.2) | .999 |
| Thyroid conditions | 0 (0.0) | 3 (1.8) | .553 |
| Health problems preventing physical activity, %g | |||
| Back problems prevent physical activity | 2 (2.6) | 4 (2.4) | .999 |
| Foot problems prevent physical activity | 2 (2.6) | 2 (1.2) | .595 |
| Knee problems prevent physical activity | 1 (1.3) | 4 (2.4) | .999 |
| Neck problems prevent physical activity | 1 (1.3) | 1 (0.61) | .540 |
| Asthma prevents physical activity | 0 (0.00) | 1 (0.61) | .999 |
| Other problems prevent physical activity | 2 (2.6) | 6 (3.7) | .999 |
| Baseline values for covariates and outcomes measures in this study | |||
| SF-36 health survey measures, mean (SD)h | |||
| General health | 73.0 (16.0) | 68.3 (17.9) | .050 |
| Bodily pain | 79.9 (19.0) | 80.8 (18.0) | .702 |
| Emotional well-being | 73.6 (15.7) | 72.5 (15.8) | .603 |
| Physical functioning | 92.4 (13.2) | 92.9 (11.0) | .739 |
| Role limitations due to emotional problems | 75.4 (38.2) | 80.4 (33.1) | .309 |
| Role limitations due to physical problems | 88.1 (26.6) | 89.1 (24.2) | .784 |
| Social functioning | 86.7 (19.6) | 87.3 (18.2) | .797 |
| Vitality | 53.7 (18.7) | 53.1 (21.1) | .836 |
| Ryff Purpose in Life Scale, mean (SD)i | 68.7 (9.2) | 65.8 (11.8) | .042 |
| Anthropometric measurements, mean (SD) | |||
| Weight, kg | 77.7 (19.3) | 78.4 (16.9) | .782 |
| Body mass index | 26.9 (5.5) | 27.0 (4.9) | .930 |
| Percentage body fatj | 31.4 (8.2) | 31.3 (8.8) | .974 |
| Cardiometabolic risk factors, mean (SD) | |||
| HbA1c, whole blood, % | 5.2 (0.4) | 5.3 (0.5) | .423 |
| Glucose, mg/dL | 95.0 (11.3) | 97.1 (14.7) | .243 |
| Total cholesterol, mg/dL | 184.7 (36.1) | 192.6 (37.5) | .124 |
| Triglycerides, mg/dL | 125.4 (100.2) | 108.2 (73.0) | .180 |
| HDL, mg/dLk | 59.0 (20.3) | 61.3 (19.8) | .399 |
| LDL, mg/dLl | 104.2 (32.9) | 112.5 (31.9) | .091 |
| Systolic blood pressure, mm Hg | 119.3 (15.0) | 124.5 (15.0) | .012 |
| Diastolic blood pressure, mm Hg | 77.2 (10.5) | 79.0 (9.1) | .182 |
| Sleep, mean (SD) | |||
| Sleep problems index Im | 31.0 (13.3) | 29.8 (14.7) | .560 |
| Sleep problems index IIm | 31.9 (13.3) | 30.9 (14.9) | .613 |
| Sleep adequacym | 46.8 (22.7) | 48.1 (24.1) | .703 |
| Sleep disturbancem | 29.8 (18.4) | 27.9 (19.6) | .473 |
| Optimal Sleep scalen | 0.5 (0.5) | 0.5 (0.5) | .735 |
| Sleep quantitym | 6.6 (0.9) | 6.6 (1.0) | .809 |
| Somnolence scalem | 21.9 (16.0) | 23.2 (17.1) | .607 |
| Snoring scalem | 31.4 (32.0) | 30.1 (33.1) | .785 |
| Short of breath scalem | 6.4 (12.9) | 6.7 (14.1) | .887 |
| International Physical Activity Questionnaire (IPAQ), median (IQR)o | |||
| IPAQ walking MET, min/wkp | 693.0 (709.5) | 495.0 (726.0) | .220 |
| IPAQ moderate MET, min/wkq | 360.0 (620.0) | 240.0 (480.0) | .016 |
| IPAQ vigorous MET, min/wkp | 760.0 (1440) | 320.0 (1200.0) | .015 |
| IPAQ summary scoreq | 2413.5 (1854.0) | 1398.7 (1790) | .004 |
| Mood (Profile of Mood States), median (IQR)r | |||
| Tension/anxietys | 5.0 (5.0) | 4.0 (5.0) | .500 |
| Anger/hostilitys | 2.0 (4.0) | 2.0 (4.0) | .687 |
| Fatigues | 5.0 (7.0) | 5.0 (6.0) | .702 |
| Depression/dejections | 2.0 (5.0) | 1.0 (6.0) | .912 |
| Vigort | 10.0 (7.0) | 10.0 (5.0) | .550 |
| Confusion/bewildermentt | 2.5 (4.0) | 3.0 (3.0) | .414 |
| Total mood disturbance (summary score)t | 8.0 (22.0) | 7.0 (25.0) | .842 |
| Depression: CESD total score, mean (SD)u | 10.9 (9.4) | 10.2 (8.4) | .565 |
| Percent at risk for depressionv | 20 (27.4) | 36 (22.4) | .403 |
Abbreviations: CESD, Center for Epidemiologic Studies Depression; GED, General Equivalency Diploma; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; SD, standard deviation.
aχ2 test for categorical variables and 2 sample t test for continuous variables.
bIncludes American Indian/Alaska Native, multiracial, and unknown/other.
cIncludes single, widowed, separated, divorced, other/unknown.
dUnknowns excluded from P value calculation.
eCG = 74 and IG = 163; P value is for Fisher exact test.
fCG = 73 and IG = 155.
gP value is for Fisher exact test.
hCG = 76 and IG = 163.
iCG = 76 and IG = 161.
jCG = 75 and IG = 162.
kCG = 76 and IG = 162.
lCG = 65 and IG = 135.
mCG = 72 and IG = 162.
nCG = 71 and IG = 155.
oSignificance determined using Wilcoxon 2-sample test (2-sided P value). Metabolic equivalent task (MET) expresses the intensity of a physical activity; walking MET = 3.3 × walking minutes × walking days; thus, an individual walking 30 min/d for 7 d/wk would be assigned walking MET = 3.3 × 30 × 7 = 693 MET min/wk. Summary score is sum of MET min/w for walking, moderate, and vigorous activity; IPAQ assigns walking 3.3 METs, moderate activity 4.0 METs, and vigorous activity 8.0 METs.
pCG = 72 and IG = 163.
qCG = 72 and IG = 162.
rP value is for Wilcoxon 2 sample test.
sCG = 72 and IG = 162.
tCG = 72 and IG = 161.
uCG = 73 and IG = 161.
vDefined as cut point of 16 or greater to identify individuals at risk of clinical depression.
Six-Month Change in Perceived Health and Purpose in Life.
| Control Group (CG), n = 74a | Intervention Group (IG), n = 146 | ||
|---|---|---|---|
| Adjusted percentages (95% CI) of participants scoring on average in the highest categories at 6 monthsc | |||
| SF-36 health survey measuresd | |||
| General health | 0.5 (0.4-0.6) | 0.68 (0.61-0.75) | .014 |
| Bodily pain | 0.63 (0.52-0.73) | 0.74 (0.66-0.81) | .077 |
| Mental health | 0.45 (0.32-0.58) | 0.65 (0.56-0.75) | .027 |
| Physical functioning | 0.96 (0.91-1.01) | 0.95 (0.92-0.99) | .781 |
| Role limitations due to emotional problems | 0.81 (0.73-0.89) | 0.91 (0.85-0.97) | .106 |
| Role limitations due to physical problems | 0.85 (0.78-0.92) | 0.95 (0.9-1) | .026 |
| Social functioning | 0.81 (0.74-0.88) | 0.94 (0.89-0.99) | .007 |
| Adjusted means (95% CI)c | |||
| SF-36: vitality | 4.98 (1.31-8.66) | 12.65 (10.05-15.26) | .003 |
| Adjusted means (95% CI) of 6-month changec | |||
| Ryff Purpose in Life Scalee | 0.27 (−1.49-2.02) | 5.22 (3.97-6.48) | <.001 |
Abbreviations: CI, confidence interval; SF-36, 36-item Short-Form.
a74 CG due to 1 control missing SF-36 questionnaire data.
bP values for categorical analysis computed from logistic regression.
cAll analyses adjusted for age (years), sex, ethnicity (white/nonwhite), worksite, and baseline value.
dCut points for each measure are as follows: general health ≥75, bodily pain ≥75, mental health ≥80, physical functioning ≥75, role limitations due to emotion ≥66, role limitations due to physical ≥75, social fun ≥75, and vitality ≥80.
e74 CG and 143 IG; higher score indicates more goals, sense of directedness, feelings of meaning in life, and beliefs that give life purpose.
Six-Month Change in Quality of Life Measures.
| Quality of Life Measure | Adjusted Means (95% CI)a | ||
|---|---|---|---|
| Control Group (CG) | Intervention Group (IG) | ||
| Sleepb | n = 67 | n = 136 | |
| Sleep problems index I | −1.35 (−4.17 to 1.48) | −5.42 (−7.39 to −3.45) | .024 |
| Sleep problems index II | −1.38 (−4.36 to 1.59) | −5.79 (−7.89 to −3.69) | .021 |
| Sleep adequacy | 5.08 (−1.11 to 11.28) | 7.92 (3.52 to 12.33) | .426 |
| Sleep disturbance | 0.02 (−3.43 to 3.47) | −5.63 (−8.04 to −3.21) | .013 |
| Optimal Sleep Scalec,d | −0.13 (−0.25 to −0.01) | 0.12 (0.03 to 0.2) | .004 |
| Optimal Sleep Scale at month 6c | 0.35 (0.23 to 0.47) | 0.6 (0.51 to 0.68) | .004 |
| Sleep quantitye | −0.09 (−0.3 to 0.11) | 0.15 (0 to 0.29) | .057 |
| Somnolence Scale | −1.69 (−4.66 to 1.27) | −5.2 (−7.27 to −3.13) | .054 |
| Snoring Scalef | −1.77 (−9.29 to 5.74) | −6.73 (−12.14 to −1.32) | .262 |
| Short of Breath Scale | 0.89 (−3.32 to 5.11) | −0.62 (−3.6 to 2.35) | .528 |
| Mood (POMS)g | n = 65 | n = 123 | |
| Summary score | −0.6 (−6.13 to 4.93) | −4.27 (−8.27 to −0.26) | .258 |
| Anger | −0.15 (−1.48 to 1.17) | −0.04 (−1 to 0.92) | .878 |
| Confusion | 0.06 (−0.57 to 0.69) | −0.21 (−0.67 to 0.25) | .455 |
| Depression | −0.2 (−1.7 to 1.29) | −0.29 (−1.37 to 0.79) | .920 |
| Fatigue | −0.03 (−1.24 to 1.18) | −1.75 (−2.62 to −0.87) | .027 |
| Tension | 0.47 (−0.66 to 1.59) | −0.26 (−1.08 to 0.55) | .265 |
| Vigor | 0.86 (−0.24 to 1.96) | 1.67 (0.87 to 2.47) | .211 |
| Depression | n = 65 | n = 128 | |
| Change in overall CESD score from baseline | −0.14 (−1.82 to 1.54) | −2.28 (−3.5 to −1.07) | .042 |
| Percentage at risk of depression at 6 monthsh | 25 (15 to 34) | 16 (8 to 23) | .132 |
Abbreviations: CESD, Center for Epidemiologic Studies Depression Scale; CI, confidence interval; POMS, profile of mood states.
aAll analyses adjusted for age (years), sex, ethnicity (white/nonwhite), worksite, and baseline value.
bHigher sleep quality scores reflect more of the attribute implied by the scale name.
cOptimal Sleep Scale response consisted of a yes/no response and, therefore, was not subject to outlying values.
dCG = 64, IG = 123.
eSleep quantity had limited values of 4 to 8 hours and, therefore, was not subject to outlier values.
fCG = 66, IG = 136.
gPOMS 65 question version was used; however, the final 11 questions were missing. Domains were calculated excluding missing questions so the ability to compare POMS scores with other populations is limited.
hDefined as CESD total score of 16 or higher (less than 16 indicates no risk of clinically significant depression).
Six-Month Change in Anthropometric Measurements and Cardiometabolic Risk Factors.
| Anthropometric Measurement/Cardiometabolic Risk Factor | Adjusted Means (95% CI) | ||
|---|---|---|---|
| Control Group (CG), n = 75 | Intervention Group (IG), n = 146 | ||
| Weight, kga,b | −0.03 (−0.73 to 0.67) | −0.43 (−0.92 to 0.07) | .326 |
| BMIa,b | 0 (−0.25 to 0.24) | −0.16 (−0.33 to 0.02) | .280 |
| Percent body fata,c | 0.3 (−0.28 to 0.87) | −0.38 (−0.78 to 0.02) | .058 |
| HBA1C, whole blood, %d,e | 0.11 (0.04 to 0.18) | 0.13 (0.08 to 0.18) | .748 |
| Glucose, mg/dLd | 4.21 (1.59 to 6.82) | 0.03 (−1.8 to 1.85) | .015 |
| Total cholesterol, mg/dLd | 11.06 (4.05 to 18.08) | 0.37 (−4.62 to 5.36) | .019 |
| Triglycerides, mg/dLd | 10.06 (−5.2 to 25.32) | 8.84 (−1.76 to 19.44) | .887 |
| HDL, mg/dLd,f | 3.51 (0.26 to 6.75) | −1.99 (−4.31 to 0.33) | .011 |
| LDL, mg/dLd,g | 4.84 (−1.54 to 11.21) | 0.75 (−3.78 to 5.27) | .278 |
| Systolic blood pressure, mm Hgd | 0.85 (−2.42 to 4.11) | −2.39 (−4.73 to −0.06) | .103 |
| Diastolic blood pressure, mm Hgd | −0.73 (−2.31 to 0.84) | −2.71 (−3.81 to −1.61) | .044 |
| Metabolic syndrome at month 6, %d,h | 30.4 (22.9 to 38.0) | 26.9 (21.6 to 32.2) | .416 |
Abbreviations: BMI, body mass index; CI, confidence interval; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aAdjusted for age (years), sex, ethnicity, worksite, and baseline value.
bCG = 73 and IG = 146.
cCG = 69 and IG = 141.
dAdjusted for age (years), sex, ethnicity (white/nonwhite), smoking at baseline (yes/no), medication use, worksite, and baseline value. Medication use was defined as glucose-lowering medication for HBA1C and glucose models, cholesterol-lowering medication for total cholesterol, triglycerides, HDL, and LDL models, and blood pressure-lowering medication for systolic and diastolic models. Positively skewed variables were examined on both original and logged scales with similar results. Original data are presented.
eCG = 75 and IG = 145.
fCG = 74 and IG = 145.
gCG = 58 and IG = 110.
hBased on the ATP 3 guidelines of having 3 or more of the following: waist circumference of >102 cm for men and >88 cm for women, fasting plasma triglycerides ≥150mg/dL or taking cholesterol-lowering medication, fasting HDL cholesterol <40 mg/dL for men or <50 mg/dL for women, or taking cholesterol-lowering medication, systolic blood pressure ≥130 mm Hg and/or diastolic blood pressure ≥85 mm Hg, or taking hypertension medication, fasting plasma glucose ≥100 mg/dL, or taking diabetes medication.